Stock Ticker

  • Loading stock data...

Sanofi SA (NASDAQ:SNY) Would Focus On Cancer Treatments For Rapid Growth: Sanofi In Advanced Stage To Divest Seprafilm

Sanofi SA (NASDAQ:SNY) is in advanced talks to divest Seprafilm to Baxter International Inc (NYSE:BAX). Seprafilm is valued at up to $400 million. It is used to eliminate scars resulting from pelvic and abdominal surgeries. Sanofi intends to focus on cancer treatments to achieve rapid growth. Products to reduce complications Baxter is engaged in the […]

Baxter International Inc (NYSE:BAX) To Buy Oncaspar Portfolio From Sigma-Tau For $900 Million

On Tuesday, Baxter International Inc (NYSE:BAX) announced that it had entered into a contract to buy the Oncaspar portfolio from Sigma-Taufor a hefty consideration of $900 million. The new acquisition will give the company a more established presence in the Oncology markets particularly with regards to rare conditions. Oncaspar is a component of the multiple […]

Baxter International Inc. (NYSE:BAX) Purchases Cancer Drugs For $900 Million

Due to increased market competition, Baxter International Inc. (NYSE:BAX) has decided to strengthen its portfolio. Reports claim that the company has agreed to purchase the drug portfolio of Italian drugmaker Sigma-Tau Finanziaria SpA. These drugs can be used to treat rare form of blood cancer. The deal will cost over $900 million before other expenses […]

Merrimack Pharmaceuticals Inc (NASDAQ:MACK) Ties-Up With Baxter International Inc. (NYSE:BAX) To Sell Pancreatic Cancer Drug

Boston, MA 09/25/2014 (wallstreetpr) – Merrimack Pharmaceuticals Inc (NASDAQ:MACK) seeks to work with Baxter International Inc. (NYSE:BAX) in the development and marketing of its pancreatic cancer drug outside the U.S. Terms Of Agreement According to a Reuters’ report, Merrimack and Baxter will work in partnership to expand the market of Merrimack’s pancreatic drug outside of the […]

Baxter International Inc. (NYSE:BAX) Progresses Ahead With VIVIA Haemodialysis System

Boston, MA 06/09/2014 (wallstreetpr) – Baxter International Inc. (NYSE:BAX) progresses in the terms of safety by curtailing the amount of uremic toxins that are associated with the conventional VIVIA Haemodialysis. The above was concluded only after adequate results from two major studies were collected and proved to be supporting the analysis. In Europe, December 2013; […]

Baxter International Inc. (NYSE:BAX) Goes On To Be A Global Leader In Hemophilia A

Boston, MA 06/05/2014 (wallstreetpr) – Baxter International Inc. (NYSE:BAX) is a global leader in health care services. The company caters to the needs of the people through many of its subsidiaries. These subsidiaries are actively involved in developing, manufactured and marketing products that make the health of people better thus giving them a better life […]

Baxter International Inc. (NYSE:BAX) Identified As A Pre-Market Leader

Boston, MA 10/29/2013 (wallstreetpr) – Baxter International Inc. (NYSE:BAX) is primarily a health care company that specializes in treating hemophilia, immune disorders and trauma amongst others. It is involved in both drug development and manufacture. Trade-Ideas LLC is the analyst firm hat had identified Baxter International as a pre-market stock leader. The reason for categorizing this […]

Sign Up To Get Our Latest Stocks Alerts